Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-25-105215
Filing Date
2025-11-03
Accepted
2025-11-03 07:00:26
Documents
82
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q lqda-20250930x10q.htm   iXBRL 10-Q 2164303
2 EX-31.1 lqda-20250930xex31d1.htm EX-31.1 15199
3 EX-31.2 lqda-20250930xex31d2.htm EX-31.2 15228
4 EX-32.1 lqda-20250930xex32d1.htm EX-32.1 7464
5 EX-32.2 lqda-20250930xex32d2.htm EX-32.2 7471
6 GRAPHIC lqda-20250930x10q001.jpg GRAPHIC 631
  Complete submission text file 0001104659-25-105215.txt   9389420

Data Files

Seq Description Document Type Size
7 EX-101.SCH lqda-20250930.xsd EX-101.SCH 70334
8 EX-101.CAL lqda-20250930_cal.xml EX-101.CAL 52022
9 EX-101.DEF lqda-20250930_def.xml EX-101.DEF 247833
10 EX-101.LAB lqda-20250930_lab.xml EX-101.LAB 583430
11 EX-101.PRE lqda-20250930_pre.xml EX-101.PRE 395050
85 EXTRACTED XBRL INSTANCE DOCUMENT lqda-20250930x10q_htm.xml XML 1757680
Mailing Address 419 DAVIS DRIVE, SUITE 100 MORRISVILLE NC 27560
Business Address 419 DAVIS DRIVE, SUITE 100 MORRISVILLE NC 27560 919.328.4400
Liquidia Corp (Filer) CIK: 0001819576 (see all company filings)

EIN.: 851710962 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39724 | Film No.: 251442065
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)